• 1
    Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32: 42336.
  • 2
    Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 42241.
  • 3
    Neary PM, Hallihan P, Wang JH, Pfirrmann RW, Bouchier-Hayes DJ, Redmond HP. The evolving role of taurolidine in cancer therapy. Ann Surg Oncol 2010; 17: 113543.
  • 4
    Jacobi CA, Menenakos C, Braumann C. Taurolidine—a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005; 16: 91721.
  • 5
    Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs 2007; 25: 30512.
  • 6
    Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61: 681621.
  • 7
    Nici L, Monfils B, Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 2004; 10: 765561.
  • 8
    Abramjuk C, Bueschges M, Schnorr J, Jung K, Staack A, Lein M. Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. Oncol Rep 2009; 22: 40914.
  • 9
    Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi CA. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis 2005; 22: 7783.
  • 10
    Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 2004; 24: 11437.
  • 11
    Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi CA. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 2006; 4: 34.
  • 12
    Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000; 18: 26171.
  • 13
    Arlt MJ, Banke IJ, Walters DK, Puskas GJ, Steinmann P, Muff R, Born W, Fuchs B. LacZ transgene expression in the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of micrometastasis. J Orthop Res 2011; 29: 93846.
  • 14
    Darnowski JW, Goulette FA, Cousens LP, Chatterjee D, Calabresi P. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 2004; 54: 24958.
  • 15
    Jacobi CA, Ordemann J, Bohm B, Zieren HU, Sabat R, Muller JM. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. Am J Surg 1997; 174: 35963.
  • 16
    McCourt M, Wang JH, Sookhai S, Redmond HP. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000; 7: 68591.
  • 17
    Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005; 23: 9649.
  • 18
    Chromik AM, Huss S, Osseili H, Daigeler A, Kersting S, Sulberg D, Mittelkotter U, Herdegen T, Uhl W, Muller AM. Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice. J Carcinog 2010; 9: 5.
  • 19
    Braumann C, Ordemann J, Wildbrett P, Jacobi CA. Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. Clin Exp Metastasis 2000; 18: 54752.
  • 20
    Reinmuller J. [The influence of taurolidine on physiological and pathological blood coagulation and implications for its use]. Zentralbl Chir 1999; 124( Suppl 4): 138.
  • 21
    Jacobi CA. Taurolidin in der Tumortherapie. Vorstellung eines neuen Therapiekonzeptes, 1st edn., Bremen: UNI-MED Verlag, 2003.
  • 22
    Erpek H, Tuncyurek P, Soyder A, Boylu S. Hyaluronic acid/carboxymethylcellulose membrane barrier versus taurolidine for the prevention of adhesions to polypropylene mesh. Eur Surg Res 2006; 38: 4147.
  • 23
    Bahadir I, Oncel M, Kement M, Sahip Y. Intra-abdominal use of taurolidine or heparin as alternative products to an antiadhesive barrier (Seprafilm) in adhesion prevention: an experimental study on mice. Dis Colon Rectum 2007; 50: 220914.
  • 24
    Tarhan OR, Barut I, Sezik M. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. J Surg Res 2008; 144: 1517.
  • 25
    Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A. T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay? J Exp Med 1986; 164: 107592.
  • 26
    Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y, Frei K. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 2009; 5: 194210.
  • 27
    Kirsch LE, Sihn YS. The effect of polyvinylpyrrolidine on the stability of taurolidine. Pharm Dev Technol 1997; 2: 34556.
  • 28
    Braumann C, Gutt CN, Scheele J, Menenakos C, Willems W, Mueller JM, Jacobi CA. Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial. World J Surg Oncol 2009; 7: 32.
  • 29
    Imhof L, Goldinger SM, Baumann K, Schad K, French LE, Rothlisberger P, Dummer R. The antibacterial substance, taurolidine in the second/third-line treatment of very advanced Stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Res 2010; 21: 803.